Bruker Expands Infection Detection Portfolio with Acquisition of Metagenomic mNGS DISQVER® Platform for Pathogenic Microorganisms in Blood

Key Terms

metagenomic next-generation sequencing technical

A laboratory method that sequences all DNA and RNA in a clinical or environmental sample to identify microbes, viruses, and genetic markers without targeting any single organism. Think of it as reading every page in a library instead of checking one shelf: it reveals known and unexpected organisms and genetic features. It matters to investors because the technique underpins broad, fast diagnostics, infectious-disease surveillance, and research tools that can drive commercial diagnostics, therapeutics development, and related regulatory and reimbursement decisions.

mngs technical

mNGS (metagenomic next-generation sequencing) is a laboratory method that reads all genetic material in a sample to identify bacteria, viruses, fungi, and other organisms without targeting any one pathogen. Like taking a high-resolution aerial photo that shows every building rather than looking for a specific address, it helps uncover unexpected or multiple infections and molecular markers. For investors, mNGS matters because it influences diagnostic product development, clinical adoption, regulatory review, reimbursement prospects, and the commercial value of companies working in infectious disease and molecular diagnostics.

whole genome sequencing technical

Whole genome sequencing is a laboratory method that reads an individual’s complete DNA instruction book, capturing all genetic letters rather than just selected parts. For investors, it matters because it can reveal new ways to diagnose, prevent or treat disease and to develop tests or drugs — like upgrading from a map of a few streets to a full city blueprint — which can create commercial opportunities, influence regulatory pathways and change healthcare costs and demand.

cell-free dna medical

Fragments of DNA that float freely in the bloodstream after being released by dying or damaged cells, like puzzle pieces carried downstream that hint at what’s happening upstream. Investors care because measuring these fragments enables non‑invasive tests — for example to detect cancer, monitor treatment response, check pregnancy health, or spot organ rejection — so advances, approvals, or reimbursement changes can quickly affect companies that develop the tests and related technologies.

antimicrobial susceptibility testing medical

Antimicrobial susceptibility testing is a laboratory process that checks which antibiotics or antifungal drugs can stop a specific microbe from growing, like testing keys to see which one opens a lock. For investors, the results drive which treatments hospitals buy, influence drug labeling and regulatory approval, and reveal resistance trends that can shrink or expand market demand for medicines and diagnostic tools.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

The DISQVER® platform provides advanced bioinformatics and reporting to support rapid and comprehensive WGS analysis directly from cell-free human blood samples

DISQVER^® enables metagenomic next-generation sequencing (mNGS) analysis of microbes directly from blood samples, further expanding Bruker's NGS-based infection detection capabilities. Without any need for prior cultivation, DISQVER analyzes whole genome sequencing (WGS) data and applies advanced, proprietary bioinformatics to search for more than 11,000 different microbes and parasites. The mNGS analysis can be done directly from cell-free DNA samples from blood, in less than 24 hours after sample receipt. This advanced mNGS clinical research approach can be valuable for bloodstream infections, sepsis, endocarditis, and other severe infectious diseases.

Following the acquisition, DISQVER^® remains available for research use only, while Bruker is progressing its registration for diagnostic purposes. Financial details of the transaction were not disclosed, and DISQVER^® is not expected to be material to Bruker’s FY26 financial results.

Dr. Wolfgang Pusch, President of Bruker Microbiology & Infection Diagnostics, commented: “The acquisition of the DISQVER^® proprietary software and workflow platform is the latest step in our evolution as an innovative microbiology and molecular diagnostics business. We have expanded into rapid antimicrobial susceptibility testing (AST), hospital hygiene testing, sample-to-answer molecular diagnostics with the ELITech Genius platform, and most recently into NGS for infectious disease testing. DISQVER^® adds additional NGS applications to our portfolio for metagenomics, and enhances our support for earlier decision-making in sepsis, bloodstream infections, and severe infections."

About Bruker Corporation – Leader of the Post-Genomic Era (Nasdaq: BRKR)

Bruker is enabling scientists and engineers to make breakthrough post-genomic discoveries and develop new applications that improve the quality of human life. Bruker’s high-performance scientific instruments and high value analytical and diagnostic solutions enable scientists to explore life and materials at molecular, cellular, and microscopic levels. In close cooperation with our customers, Bruker is enabling innovation, improved productivity, and customer success in post-genomic life science molecular and cell biology research, in applied and biopharma applications, in microscopy and nanoanalysis, as well as in industrial and cleantech research, and next-gen semiconductor metrology in support of AI. Bruker offers differentiated, high-value life science and diagnostics systems and solutions in preclinical imaging, clinical phenomics research, proteomics and multiomics, spatial and single-cell biology, functional structural and condensate biology, as well as in clinical microbiology and molecular diagnostics. For more information, please visit www.bruker.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260715763519/en/

Trade Press & Customer Contact:
Alessandro Abramo
Director Marketing & Product Management
Bruker Microbiology & Infection Diagnostics
T: +39-348-360-9058
E: alessandro.abramo@bruker.com

Investor Contact:
Joe Kostka
Director, Investor Relations & Corporate Development
Bruker Corporation
T: +1 (978) 313-5800
E: Investor.Relations@bruker.com

Source: Bruker Corporation